Although EPO and G-CSF have been commonly used individually as hematopoietic growth factors in the treatment of anemia and neutropenia, these pharmacological agents have been recently reported to have neuroprotective and regenerative potential as neurotrophic factors in stroke [27,31,32]. The gene discussed is CSF3; the disease is neutropenia.